GLP-1 Drugs and Low Blood Sugar: Who Is Actually at Risk

If a GLP-1 is the only glucose-lowering drug you take, low blood sugar is an unlikely problem. These drugs prompt insulin release in response to glucose, so when glucose is not high they largely stop prompting. The risk arrives with what sits beside them. The Wegovy label is explicit about which company it keeps: put a sulfonylurea, or insulin, in the picture and hypoglycemia becomes more likely. It tells prescribers to consider cutting that other dose at the point the GLP-1 starts.^[1] Metformin is not on that list; where it does overlap with a GLP-1 is covered in metformin and a GLP-1 together.

Why the mechanism matters here

Insulin, and the sulfonylureas the label groups as insulin secretagogues, lower blood glucose whether or not it needs lowering. That is what makes them capable of driving it too far down. A GLP-1 works differently: its effect on insulin secretion is glucose-dependent, which is the technical way of saying it largely stands down when glucose is normal.

The largest ongoing comparison of diabetes medicines — a living network meta-analysis in the BMJ, updated at least twice a year — reflects exactly that. It names sulfonylureas, insulin and DPP-4 inhibitors as probably increasing the risk of severe hypoglycemia.^[2] GLP-1 receptor agonists are not in that list.

The drug that lowers your blood sugar too far is usually the one you were already taking. The GLP-1 changes how much of it you need.

What the label actually counted

“Unlikely” is not “never”, and the label does not pretend otherwise. In its trial of adults who had type 2 diabetes alongside a BMI of 27 or above, hypoglycemia — defined as plasma glucose below 54 mg/dL — was reported in more patients on Wegovy than on placebo. One episode of severe hypoglycemia, meaning it required another person’s help, occurred in a treated patient, against none on placebo.^[1]

One episode is a small number and it is not zero. It is also from the population where this matters — people who have diabetes as well as excess weight, and who are therefore likely to be on other glucose-lowering drugs already.

The combination the label has not tested

This is the sentence worth knowing, and it is easy to read past. The label states that the use of Wegovy in patients with type 1 diabetes, or in combination with insulin, has not been evaluated.^[1]

Not contraindicated. Not warned against. Untested. Those are different claims, and the difference matters because people reasonably assume that an approved drug has been studied in the combination they are personally taking. Anyone using a GLP-1 alongside insulin is outside what the trials examined, whatever their prescriber has concluded is right for them.

What the label asks a prescriber to do

1. Check glucose before starting, and during. For patients with diabetes the label asks for monitoring at both points, not just afterward.^[1]
2. Consider a smaller dose of the sulfonylurea or insulin from the day the GLP-1 begins. The label frames this as something to weigh when the GLP-1 starts, rather than a change to make after a low reading.^[1]
3. Teach the symptoms. The label asks prescribers to inform patients of the risk and educate them on the signs, which implies you should have been told and can ask if you were not.

Knowing it when it happens

Shakiness, sweating, a racing heart, sudden hunger, confusion, irritability or difficulty concentrating. Severe episodes can progress to an inability to treat yourself, which is what the label means by requiring another person’s assistance. A racing heart without those other signs has other explanations on these drugs, covered in GLP-1 heart rate and palpitations.

There is a wrinkle specific to these drugs. GLP-1 medicines slow how quickly the stomach empties, which is also how quickly a fast-acting carbohydrate reaches the bloodstream. That does not change what you should do about a low reading — it is a reason to raise the question with whoever manages your diabetes, since the usual timing assumptions may not hold. A fast long enough to matter changes that arithmetic, and the only place it has been studied is Ramadan — what the four Ramadan studies actually tested is narrower than it is usually reported to be.